Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

98.83 +9.56 (+10.71%)
Official Closing Price Updated: 4:10 PM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street ↗
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares. 
Via MarketBeat
News headline image
Dow Jones Hangs On While Memory Chips Take Another Beating ↗
Why is the Dow holding up while the Nasdaq sinks? Healthcare gains are offsetting the semiconductor carnage. 
Via The Motley Fool
Topics Stocks
Unusual volume S&P500 stocks in Thursday's session ↗
Via Chartmill
Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance ↗
Via Chartmill
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income ↗
Via Chartmill
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Abbott Laboratories Q2 Earnings Call Highlights ↗
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying... 
Via MarketBeat
Topics Earnings
News headline image
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings... 
Via Benzinga
Topics Earnings
News headline image
Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales
Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ... 
Via StockStory
Topics Artificial Intelligence
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions. 
Via The Motley Fool
News headline image
5 Dividend Kings to Buy in July with Irristable Value and Yield ↗
Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds. 
Via MarketBeat
News headline image
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
Don't sleep on these medical device leaders. 
Via The Motley Fool
Topics Supply Chain
News headline image
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years ↗
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence. 
Via The Motley Fool
News headline image
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio ↗
These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
If You Put $10,000 in This Dividend ETF 15 Years Ago, Here's How Much You'd Have Today (Hint: It's a Lot) ↗
The Schwab U.S. Dividend Equity ETF is anything but boring. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy. 
Via The Motley Fool
News headline image
3 Magnificent Dividend ETFs That Could Supercharge Your Passive Income ↗
All three ETFs complement each other well in a portfolio. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 ↗
Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot. 
Via The Motley Fool
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
These healthcare stocks may be the building blocks of a winning portfolio. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? ↗
July earnings matter, but long-term growth matters more. 
Via The Motley Fool
News headline image
3 High-Yield Dividend Stocks to Buy Hand Over Fist in June ↗
Now's the time to load up on these high-yielders. 
Via The Motley Fool
Topics Economy
News headline image
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months ↗
Analysts remain relatively more upbeat, but this could prove fleeting. 
Via The Motley Fool
News headline image
New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around ↗
Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term. 
Via The Motley Fool
Topics Credit Cards Economy
News headline image
Can Beyond Meat's Pivot to Protein Drinks Change the Investment Thesis? ↗
Declining sales of plant-based meats have the company looking for other revenue sources. 
Via The Motley Fool
News headline image
Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗
Grail is on a quest to win in a $50 billion market. 
Via The Motley Fool
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering. 
Via The Motley Fool
Topics Intellectual Property Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.